UNSPSC 51332520: Haloperidol lactate

This classification denotes a dopamine antagonist with the molecular formula C21H23ClFNO2.C3H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6387S86PK3, chemically known as 1-butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)- but more generally known as haloperidol lactate, which bears US NIH Compound Identifier 3559. European Medicines Agency schedules Haloperidol lactate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02453MIG.

UNSPSC 51332520 Haloperidol lactate is a Commodity code that in practice encompasses pharmaceutical procurement across state and local health agencies, though recent opportunities show minimal activity directly tied to this specific drug. State and local governments purchase pharmaceuticals through this code as part of broader health-system supply chains, but the recent solicitations recorded here reflect purchase activity at the multi-source generics and emergency-response medication level rather than haloperidol specifically. Issuing bodies soliciting pharmaceutical products include state health departments (Texas Health and Human Services Commission), county health systems (Seminole County, Florida), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The cooperative purchasing vehicle appears to dominate recent activity, with MMCAP coordinating multi-state pharmaceutical procurement across participating jurisdictions including Oregon.

Geographic activity concentrates in Texas, Florida, and Minnesota, with MMCAP's cooperative structure extending reach across multiple states. Recent opportunities include the Minnesota Department of Administration's MMCAP RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, requiring vendors to supply through authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson) with awards effective July 1, 2026; Seminole County's IFB for naloxone and drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually), due July 26, 2023; and the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs, due April 3, 2026. The MMCAP procurement emphasizes fixed pricing, price competitiveness (weighted at 75 percent of evaluation), cGMP and Drug Supply Chain Security Act certification, and maintenance of chargeback systems with multiple authorized wholesalers. Vendors pursuing this code should expect multistate cooperative structures, requirement for relationships with established pharmaceutical wholesalers, compliance with federal manufacturing and supply-chain regulations, and evaluation heavily weighted to cost.